# CINSARC Genomic Signature as Predictor of Resectability of Ovarian Adenocarcinoma

> **NCT04248231** · — · COMPLETED · sponsor: **Institut Claudius Regaud** · enrollment: 150 (actual)

## Conditions studied

- Ovarian Adenocarcinoma

## Interventions

- **OTHER:** CINSARC signature

## Key facts

- **NCT ID:** NCT04248231
- **Lead sponsor:** Institut Claudius Regaud
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-15
- **Primary completion:** 2020-09-15
- **Final completion:** 2021-12-23
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2022-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04248231

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04248231, "CINSARC Genomic Signature as Predictor of Resectability of Ovarian Adenocarcinoma". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT04248231. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*